221 related articles for article (PubMed ID: 35961708)
21. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
22. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms.
Mounajjed T; Zhang L; Wu TT
Hum Pathol; 2013 Apr; 44(4):542-50. PubMed ID: 23079207
[TBL] [Abstract][Full Text] [Related]
23. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
24. Tumor-associated macrophages in liver cancer: From mechanisms to therapy.
Cheng K; Cai N; Zhu J; Yang X; Liang H; Zhang W
Cancer Commun (Lond); 2022 Nov; 42(11):1112-1140. PubMed ID: 36069342
[TBL] [Abstract][Full Text] [Related]
25. Cancer-Associated Fibroblasts in Hepatocellular Carcinoma and Cholangiocarcinoma.
Ying F; Chan MSM; Lee TKW
Cell Mol Gastroenterol Hepatol; 2023; 15(4):985-999. PubMed ID: 36708970
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY
Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
28. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
Komuta M
Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
[TBL] [Abstract][Full Text] [Related]
29. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.
Sirica AE; Strazzabosco M; Cadamuro M
Adv Cancer Res; 2021; 149():321-387. PubMed ID: 33579427
[TBL] [Abstract][Full Text] [Related]
30. Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma.
Coulouarn C; Clément B
J Hepatol; 2014 Jun; 60(6):1306-9. PubMed ID: 24530649
[TBL] [Abstract][Full Text] [Related]
31. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
[TBL] [Abstract][Full Text] [Related]
32. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
Sun H; Xing C; Jiang S; Yu K; Dai S; Kong H; Jin Y; Shan Y; Yang W; Wang Z; Xiao J; Wang H; Wang W; Li Z; Shi K
Front Immunol; 2022; 13():963031. PubMed ID: 36059488
[TBL] [Abstract][Full Text] [Related]
33. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
[TBL] [Abstract][Full Text] [Related]
34. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells.
Polidoro MA; Mikulak J; Cazzetta V; Lleo A; Mavilio D; Torzilli G; Donadon M
World J Gastroenterol; 2020 Sep; 26(33):4900-4918. PubMed ID: 32952338
[TBL] [Abstract][Full Text] [Related]
35. Matricellular proteins in intrahepatic cholangiocarcinoma.
Sirica AE
Adv Cancer Res; 2022; 156():249-281. PubMed ID: 35961702
[TBL] [Abstract][Full Text] [Related]
36. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
37. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
[TBL] [Abstract][Full Text] [Related]
38. Immunology and immunotherapy of cholangiocarcinoma.
Greten TF; Schwabe R; Bardeesy N; Ma L; Goyal L; Kelley RK; Wang XW
Nat Rev Gastroenterol Hepatol; 2023 Jun; 20(6):349-365. PubMed ID: 36697706
[TBL] [Abstract][Full Text] [Related]
39. Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma.
Fu Y; Urban DJ; Nani RR; Zhang YF; Li N; Fu H; Shah H; Gorka AP; Guha R; Chen L; Hall MD; Schnermann MJ; Ho M
Hepatology; 2019 Aug; 70(2):563-576. PubMed ID: 30353932
[TBL] [Abstract][Full Text] [Related]
40. Hepatobiliary cancers, version 2.2014.
Benson AB; D'Angelica MI; Abrams TA; Are C; Bloomston PM; Chang DT; Clary BM; Covey AM; Ensminger WD; Iyer R; Kelley RK; Linehan D; Malafa MP; Meranze SG; Park JO; Pawlik T; Posey JA; Scaife C; Schefter T; Sigurdson ER; Tian GG; Vauthey JN; Venook AP; Yen Y; Zhu AX; Hoffmann KG; McMillian NR; Sundar H
J Natl Compr Canc Netw; 2014 Aug; 12(8):1152-82. PubMed ID: 25099447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
